Durvalumab for the management of urothelial carcinoma: A short review on the emerging data and therapeutic potential

Capucine Baldini; Stéphane Champiat; Perrine Vuagnat; Christophe Massard

doi:10.2147/OTT.S141040

Durvalumab for the management of urothelial carcinoma: A short review on the emerging data and therapeutic potential

Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, Christophe Massard

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

16 Citations (Scopus)

Résumé

Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

langue originale	Anglais
Pages (de - à)	2505-2512
Nombre de pages	8
journal	OncoTargets and Therapy
Volume	12
Les DOIs	https://doi.org/10.2147/OTT.S141040
état	Publié - 1 janv. 2019

Accès au document

10.2147/OTT.S141040

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3cdcfd8f851847dba068725a2b1cde34,

title = "Durvalumab for the management of urothelial carcinoma: A short review on the emerging data and therapeutic potential",

abstract = "Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.",

keywords = "Bladder cancer, Durvalumab, Immunotherapy, PD-L1 inhibitor, Urothelial carcinoma",

author = "Capucine Baldini and St{\'e}phane Champiat and Perrine Vuagnat and Christophe Massard",

note = "Publisher Copyright: {\textcopyright} 2019 Baldini et al.",

year = "2019",

month = jan,

day = "1",

doi = "10.2147/OTT.S141040",

language = "English",

volume = "12",

pages = "2505--2512",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

}

TY - JOUR

T1 - Durvalumab for the management of urothelial carcinoma

T2 - A short review on the emerging data and therapeutic potential

AU - Baldini, Capucine

AU - Champiat, Stéphane

AU - Vuagnat, Perrine

AU - Massard, Christophe

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

AB - Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression <12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.

KW - Bladder cancer

KW - Durvalumab

KW - Immunotherapy

KW - PD-L1 inhibitor

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85065705721&partnerID=8YFLogxK

U2 - 10.2147/OTT.S141040

DO - 10.2147/OTT.S141040

M3 - Review article

AN - SCOPUS:85065705721

SN - 1178-6930

VL - 12

SP - 2505

EP - 2512

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -